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Background: Since 2004, a national Disease Management Program (DMP) has been implemented in Germany,
which includes educational measures aimed at patients with type-2 diabetes (T2D). However, about 15-20% of
T2D patients remain in poor metabolic control. Qualitative research shows that one reason for this might be an
increasing frustration of general practitioners (GPs) with the management of their poorly regulated T2D patients
over time. We aim at approaching this problem by improving the GP-patient-communication and fostering shared
decision-making.
Methods/Design: An educative intervention will be tested within a multi-centred cluster-randomized controlled
trial (RCT) in Germany. We include 20 GPs in three regions. Each of the 60 GPs will recruit about 13 patients
meeting the inclusion criteria (total of 780 patients). GPs allocated to the intervention group will receive a peer-visit
from a specifically trained GP-colleague who will motivate them to apply patient-centred communication
techniques including patient-centred decision aids. GPs allocated to the control group will not take part in any
intervention program, but will provide care as usual to their patients. The primary inclusion criterion for patients at
the time of the recruitment is an HbA1c-level of over 8.0. Primary outcome is the change of HbA1c at 6, 12, 18, and
24 months compared to HbA1c at baseline. Secondary outcomes include patient’s participation in the process of
shared decision-making and quality of life.
Discussion: If this intervention proves to be effective it may be integrated into the existing Disease Management
Program for T2D in Germany.
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In 2004, a national Disease Management Program
(DMP) was implemented in Germany. This also includes
educational aspects for patients with type-2 diabetes
(T2D). However, we know that 15–20% of T2D patients
remain in poor metabolic control in terms of their
HbA1c level [1]. Poorly regulated HbA1c values are a
risk factor for the development of complications like
diabetic foot-syndrome, retinopathy, or cardiovascular
diseases [2].* Correspondence: eva.drewelow@med.uni-rostock.de
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distribution, and reproduction in any mediumSocio-demographical and clinical characteristics alone
(e. g. social situation, duration of disease) cannot ex-
plain why some T2D patients remain in poor meta-
bolic control. Furthermore, a number of psychosocial
factors can influence the quality of blood sugar regula-
tion. These include self-efficacy, personality traits, dif-
ferent coping strategies, various dimensions of stress
and social support as well as the relationship to the
GP. Also, a flagging involvement of the physician in
managing his/her patients has been discussed as another
possible reason for constantly poor metabolic control
[3-27].
The relationship to and the communication with the
GP in the conversation can influence health parameters
in general [28]. As Alazri and Neal found, there is atral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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and better blood sugar values [29].
Interventions focussing on knowledge transfer and
understanding the pathophysiology of diabetes seem to
have only little impact (e.g. in terms of reaching thera-
peutic goals) on T2D patients (especially for the non-
compliant group) [30,31]. Interventions focussing on the
doctor and his practice seem to be promising, in particu-
lar when combined with a strong patient-centeredness.
Currently, few studies verify these effects on the patient-
level (e. g. HbA1c) [32]. Many factors and influencing
variables show contradictory effects or were explored
in only a few studies with clear methodological limita-
tions. Still, some factors seem to be relevant and promis-
ing within the framework of interventions in primary
health care.
The continuity of the GP-patient-relationship [33]
appears suitable for getting in contact with poorly regu-
lated T2D patients [29]. But sometimes the decreasing
involvement and interest of GPs in these patients results
in conversations not addressing relevant or conflict-
laden issues sufficiently [34].
As shown in the literature, reaching poorly regulated
T2D patients and improving their adherence can be fos-
tered by several factors:
a. The GP should be aware of the patient’s illness
concepts and keep their significance in mind
when dealing with the patient’s disease [35,36].
b. The use of a patient-centred communication
behaviour [37,38] (use of evidence-based
decision-aids) [39] in the consultation can
help reaching the “non-compliant” and
complicated patients.
c. Strengthening the perception of the patients’
self-efficacy, “What can I adopt for everyday life
and how?” (e.g. good diabetes regulation) [6,7],
also seems to be relevant in this context.
Systematic studies over the last 20 years have provided
evidence that there is no patent remedy for “successful”
interventions to change the behaviour of the GP. But it
is indisputable that a successful educative intervention
needs to be tailored to the target group in order to im-
plement evidence-based guidelines and patient-centred
decision-making [40-43].
Starting point of DEBATE: We know that patients
with poor metabolic control and their GPs have often
given up on improvement. Due to their gradually
built up daily routine they do not see any new pos-
sibilities to improve poor blood sugar values [44].
Within this study we want to change the communication
behaviour of GPs to foster shared decision-making com-
bined with a lasting patient empowerment. This study’saim is to verify whether this intervention targeting at
GPs is able to:
a. Reduce the HbA1c-value of the included patients by
0,5 compared to the control group.
b. Increase the participation level of the patients in the
process of shared-decision making.Methods/Design
Design of the study
An educative intervention will be tested under real con-
ditions in a primary care setting within the frame-
work of a cluster-randomized controlled study. First
the participants (GPs and their patients) are recruited
and baseline data will be recorded. This is followed
by the randomisation of the participating GPs into
intervention- and control group. Then data will be
recorded at four different measure points (6,12,18,24
months after baseline). GPs allocated to the control
group will not take part in any intervention program,
but will treat their patients as usual. Patients of those
GPs randomized into the intervention group will receive
substantial empowerment. It has to be taken into con-
sideration that the recruitment of the GPs and their
patients for the study already presents a first interven-
tion, because of the higher attention paid to the prob-
lem, by patients and GPs.Recruitment
GPs
The responsible KVa in every study area provides a
list of all GPs taking part in primary care. By sending in-
vitation letters, scientific staff in the three study centres
performs different waves of recruitment consecutively
until the target number is reached. Each study centre
recruits 20 GPs from its catchment area for the study
(total = 60).Patients
A computer-generated list will be compiled/created to
identify all the eligible patients per practice formally
complying with the inclusion criteria. A total number
of 780 patients will be needed. For GPs with more than
15 poorly regulated T2D patients on their list, a random
sample will be created and the list will also be stratified
by gender. Then the GPs consecutively keep inviting
their eligible patients until the target number of 13 per
practice is reached. Finally, the data will be transferred
to the responsible study centre Table 1.
The GPs and patients can end their participation in
the study at any time. The treatment of patients who
leave the study is guaranteed.
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
On patient-side Diabetes mellitus type 2 Severe co-morbidity
with a life expectancy
of less than 24 monthsHbA1c-level over 8.0
at the time of recruitment








aKV-Zulassung = admission of the Association of Statutory Health Insurance
Physicians/permission of the panel doctor’s association.
Table 2 Measure points for data collection
T0 T1 T2 T3 T4
HbA1c x x x x x
EQ-5D and PAID x x x
PEF-FB-9, PACIC-D x x x x x
BÄK questionnaire x x
Pharmacotherapy x x x
Cardiovascular risk prognosis x x x
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Assuming a residual standard deviation of 0.9 a case
number of 2x 143 (=286) patients is required to realize a
randomized study on the patient-side to show a differ-
ence in the HbA1c of 0.5 with a statistical power of 80%.
Due to the design of the study (cluster-randomized study
with an intervention on the GPs-side) the resulting
cluster-effects according to the case number have to
be taken into account. The derived factor will be 1.9
assuming an ICC of 0.1 and an average cluster-size
of 10. Assuming an average dropout rate of approx.
20%, it is necessary to recruit at least 54 GPs, who
treat 13 patients each in order to assure no less than
10 eligible patients per GP [45]. The recruitment of
60 practices is required assuming a practice-drop-out
rate of 10%. In order to achieve the calculated sample
size (n = 780 patients) the study was designed as a
multi-centred study with study centres in Rostock,
Düsseldorf and Witten (Institute of General Practice at
Rostock University, Institute of General Practice at the
Heinrich-Heine University in Düsseldorf, Institute of
General Practice and Family Medicine at the University
of Witten/Herdecke).
Randomisation
After the baseline data collection the GPs will be rando-
mized into intervention- and control group.
Instruments
Further instruments will be used in both groups to
measure e.g. the quality of life, the participation within
the process of medical decision-making and the em-
powerment of the patients. The instruments which are
utilized are the EQ-5D (measuring the patients health
status), the PAID (focussing on the problem areas in
Diabetes) the PEF-FB-9 (measuring the congruence of
the consultation results and the values or the attitudes
of the patients) and the internationally used PACIC-D
(measuring aspects of empowerment). At the differentpoints of measurement (T0-T4) a project assistant will
contact the patients by phone to disseminate the data
with the help of the listed instruments. Additionally, the
shortened version of a questionnaire (BÄK question-
naire), developed within a former diabetes project, will
be used at baseline (T0) and at the end (T4) of the study
to measure how patients live with diabetes [46].Data collection/-recording/-transferring
Data collection will take place at different measure
points: T0-T4 (6, 12,18 and 24 months after the base-
line = T0). The intervention (peer-visit) will take place
after the baseline, close to T1 (see intervention).
The following data will be collected at T0 (=baseline):
Concerning the GP: age, gender, time since the practice
was established, specialist title, characteristics of the
practice, the GP’s marital status and the number of
his/her children.
Concerning the patient: age, gender, socio-
demographic basic data (educational background,
profession, income, marital status, number of children),
date of the first diagnosis, pharmacotherapy, initial
HbA1c-level, cardiovascular risk prognosis, quality of
life (EQ-5D, PAID and BÄK questionnaire), the
previous involvement in decision-making processes
(PEF-FB-9 and PACIC-D).
The GPs or the GPs’ assistants will collect further details
(on): the glycated haemoglobin levels (HbA1c); data
needed to determine the cardiovascular risk prognosis
(smoking status, familiar predisposition for coronary heart
disease (CHD), blood pressure, total cholesterol, HDL
cholesterol, LDL cholesterol), pharmacotherapy.
The project’s research assistants will contact the
patients by phone and collect all the remaining data
(incl. medication taken according to the patient), by
means of standardized instruments. The collected data
will be recorded in a documentation sheet before being
transferred into a saved database.
The data will be collected at the following points in
time Table 2:
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The aim of the educative intervention is to enable the
participating GPs to identify the agenda and the illness
concepts of the patients suffering from poorly regulated
diabetes mellitus type 2 and thereby to foster shared-
decision making. The focus needs to be more on the
patient’s perspective in order to move away from the
routine of a more GP-focussed communication without
overstraining or unsettling both GPs and patients [47].
For this purpose, a change in the GPs’ communication
patterns is necessary. The educational peer-visit presents
an integral part of the intervention. Practicing GPs will
be specially trained before serving as a peer and doing
the educational outreach visit. The peer visit is then sup-
posed to motivate and train the GP in regard to the
communicational aspects of the encounter in the GP’s
practice, as described in detail in the background sec-
tion. The GP will also be trained to reflect upon differ-
ent aspects of the disease and its treatment together
with the patient. The training concept follows the Elab-
oration Likelihood Model [48]. In our preliminary
studies we have verified the acceptance of the visits
and the positive effects the peer educational outreach
visit has on doctor-patient-communication [49].
GPs allocated to intervention will be provided with a
computer-based decision-aid, which specifically addresses
diabetes and its relation to cardiovascular risk. It is based
on the already available tool arriba [50]. The communica-
tion tool is meant to be used within the consultation to
demonstrate the absolute effects of lifestyle changes and
pharmacotherapy in regard to macrovascular event likeli-
hood. [51,52]. Utilizing the decision aid may lead to a
more patient-centred communication and enable patients
to participate in the decision-making on life-style changes
and pharmacotherapy. GPs allocated to intervention will
be invited to take part in two group-training sessions
to deepen the content of the educational peer visit.
Outcome measures
Primary endpoint will be the HbA1c-level at the time of
the follow-up examinations (T1 = 6 months, T2 =
12 months, T3 = 18 months, T4 = 24 months after base-
line). The null hypothesis: the difference of the HbA1c-
value of the intervention- and the control group is not
higher or lower than 0,5; alternative hypothesis: the
HbA1c-value of the intervention group differs at mini-
mum 0,5 from the HbA1c-value of the control group.
Secondary endpoints will include the survey about
patients’ quality of life (BÄK questionnaire, EQ-5D, PAID),
about the patient-centeredness (PEF-FB-9 and PACIC-D),
and about the participation of the patients [53-57]. Data
on the calculated cardiovascular risk prognosis and pre-
scribed drugs will also be analyzed.Statistical analysis
All analyses will be performed in the ITT-population
(intention-to-treat). Instead of the patients, the GPs and
their practices will be randomized into clusters. Hence,
for the primary analysis, a mixed model with repeated
measurements will be adapted at the HbA1c-values of
the follow-up. This model includes three levels of hier-
archy: GP/practice, patients in the GP’s practice,
repeated measurements on the patient-side. Any un-
structured covariance matrix will be allowed/admitted
for the repeated measurements. First the initial value will
be the covariate of the model. An additional covariate
on the patient- or GP-level will already be included in
the primary analysis, because maldistributions are more
typical for cluster-randomized studies than for individu-
ally randomized studies. They will be selected right after
the patient recruitment has been finalised - considering
the baseline values, but without knowing the follow-up
values. The coefficient test, comparing the baseline-
adjusted final HbA1c-values between the randomized
groups, will be performed within the primary anal-
ysis. We will use the direct Maximum-Likelihood as
the statistical estimation procedure, which results in
unbiased estimated values under the missing-at-random-
assumption. Alternatively, sensitivity analyses such as last-
observation-carried-forward (LOCF) and other worst-case
scenarios will be determined. A difference of 0,5%
(HbA1c) between the groups will be considered clinically
relevant. Depending on their measurement scales the sec-
ondary endpoints will be analyzed with analogue models
up to the primary endpoint.
Quality assurance (safety board, gender-specific aspects,
interference factors)
The data safety monitoring board (DSMB) will consist of
three scientists (one biostatistician and two GPs), who
are not associated with the participating institutions
performing the study. Based on the interims-analyses of
the outcomes the DSMB can vote for a discontinuation
of the study.
Some studies refer to gender-specific risk factors and
consequences of diabetes [58-60]. To take these into
account we will perform analyses stratified by gender.
On the level of data analysis we will test whether the
intervention reaches the poorly regulated patients with
diabetes mellitus type 2 and to what extent. Gender-
specific differences might also exist and be relevant for
the empowerment-potential.
Confounding variables will primarily be controlled by
the randomization. Unevenly allocated characteristics
of patients or doctors will be included in the primary as-
sessment model, since the maldistribution of cluster-
randomized studies cannot be ignored and therefore
needs to be taken into consideration. Potential
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will, on the one hand, be minimized by standardizing
the study process and handed over essential parts of the
documentation to the study assistants. On the other
hand, quality assurance measures will be performed
within the course of the study. No information regarding
the specific hypothesis of the study and the relevance of
primary/secondary endpoints will be given to patients
and GPs.
Ethics approval
The study was approved by the Ethic Committee of the
University of Rostock on 25th of May 2011.
GPs (after the recruitment procedure) and patients
(after the conversation with the GP) will have to sign an
informed consent form to participate in the study.
Should any patients prematurely cancel the participation
in the study they will still receive their medical treat-
ment as usual from the GP.
Discussion
At this point, no intervention on the improvement of
primary health care of patients with poorly regulated
diabetes mellitus type 2 has been positively tested
in Germany. Most of the GPs continuously use the exist-
ing DMP-diabetes module for many of their patients
with diabetes. If the designed educative intervention
proves to be essentially effective it could be implemented
as an important adjunct to the existing DMP module.
Our findings will contribute to the optimization of the
primary health care routine for the target group. Since
our findings are bound to shape the medical conversa-
tion concerning content and structure, a higher effi-
ciency can be expected. The position of chronically ill
patients as participating and acting subjects will be
fostered; this will make a contribution to the improve-
ment of primary health care especially for socially disad-
vantaged patients by means of a changed, participating
communication and increasing competence levels in
self-management.
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